Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Lennox, Belinda R
The Lancet Psychiatry
MetadataShow full item record
Khandaker, G., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. (2014). Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. The Lancet Psychiatry, 2 258-270. https://doi.org/10.1016/S2215-0366(14)00122-9
Complex interactions between the immune system and the brain may have important aetiological and therapeutic implications for neuropsychiatric brain disorders. A possible association between schizophrenia and the immune system was postulated over a century ago, and is supported by epidemiological and genetic studies pointing to links with infection and inflammation. Contrary to the traditional view that the brain is an immunologically privileged site shielded behind the blood-brain-barrier, recent studies have demonstrated complex interactions between the immune system, systemic inflammation and the brain that can lead to changes in mood, cognition, and behaviour. Here, we review some of the important areas of research regarding innate and adaptive immune response in schizophrenia and related psychotic disorders that, we think, will be of interest to psychiatric clinicians and researchers. We discuss potential mechanisms and therapeutic implications of these findings including studies of anti-inflammatory agents in schizophrenia, highlight areas for development, and offer testable hypothesis for future investigations.
Inflammation, infection, immunity, autoimmunity, inflammatory markers, C-reactive protein, CRP, Interleukin 6, IL-6, antibody, NMDA receptor, cytokine, lymphocyte, macrophage, microglia, microbiota, innate immunity, adaptive immunity, dopamine, glutamate, neurodevelopment, neurodegeneration, schizophrenia, psychotic disorders, treatment, anti-inflammatory agent, immuno-psychiatry
The work was supported by a doctoral clinical research training fellowship grant from the Wellcome Trust to Golam Khandaker (094790/Z/10/Z; 2010-‘13), grants from the Stanley Medical Research Institute and the National Institutes of Mental Health (grant# MH-94268) to Robert Yolken, and grants from the Wellcome Trust (095844/Z/11/Z & 088869/Z/09/Z), and the NIHR (RP-PG-0606-1335) to Peter Jones.
Wellcome Trust (088869/Z/09/Z)
Wellcome Trust (094790/Z/10/Z)
Wellcome Trust (095844/Z/11/Z)
MEDICAL RESEARCH COUNCIL (MR/J012939/1)
Wellcome Trust (093875/Z/10/Z)
External DOI: https://doi.org/10.1016/S2215-0366(14)00122-9
This record's URL: https://www.repository.cam.ac.uk/handle/1810/246288